No Data
Haisco Pharmaceutical Group (002653.SZ) received industrial support funds of 43.9341 million yuan.
Haisco Pharmaceutical Group (002653.SZ) released an announcement that the company and its subsidiary Tibet Haize Marketing Management Co., Ltd. ("Tibet..."
The Three-year Decline in Earnings Might Be Taking Its Toll on Haisco Pharmaceutical Group (SZSE:002653) Shareholders as Stock Falls 6.9% Over the Past Week
Haisco Pharmaceutical Group (002653.SZ): has obtained the "Notice of Drug Clinical Trial Approval" for the innovative drug HSK46575 tablets.
On December 4th, Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The tablet is named HSK46575 Tablet and is intended for the treatment of prostate cancer. HSK46575 Tablet is a self-developed oral, potent, and highly selective small molecule inhibitor designed for the treatment of prostate cancer. Preclinical research results indicate that this product has a clear target, precise efficacy, and good safety profile, making it a highly promising small molecule drug with significant potential for development. The benefits/risks of clinical application.
haisco pharmaceutical group (002653.SZ): received a total of 75.5127 million yuan in industrial support funds
On December 1, Glonghui reported that haisco pharmaceutical group (002653.SZ) announced that the company and its subsidiary, Tibet Haize Marketing Management Co., Ltd. (hereinafter referred to as "Tibet Haize"), received a total of 75.5127 million yuan in industry support funds from the Investment Promotion Bureau of Shannan City, Tibet, on November 29, 2024, and the funds have been received. The industry support funds obtained this time are related to the company's daily operation activities and are not sustainable.
Haisco Pharmaceutical Group Sees Inclusion of Two Drugs in National Medical Insurance Catalog
Has Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
